A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease to Evaluate the Clinical Bioequivalence Between Tavapadon Tablets
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Tavapadon
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Cerevel Therapeutics
- 07 Feb 2024 Status changed from recruiting to completed.
- 24 Apr 2023 Planned End Date changed from 30 Mar 2024 to 5 Nov 2023.
- 24 Mar 2023 Planned End Date changed from 31 Oct 2023 to 30 Mar 2024.